[Clinical significance of thrombin-antithrombin III complex and plasmin-alpha 2 plasmin inhibitor complex in chronic liver diseases]. 1990

K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
Department of Medicine, Kawasaki Medical School.

Thrombin-antithrombin III complex (TAT) and Plasmin-alpha 2 plasmin inhibitor complex (PIC) were examined in fifty two cases of various chronic liver diseases. TAT was significantly elevated in cases of hepatocellular carcinoma (HCC), but PIC did not show significant changes in any chronic liver diseases. Elevations of TAT and PIC were seen in cases of HCC accompanied by tumor enlargement and extensive tumor thrombosis. In cases of HCC undergoing transcatheter arterial embolization (TAE), TAT and PIC increased on the next day after TAE, and tended to recover with time, returning to almost normal at fourth week. Prolongation of prothrombin time, elevation of FDP and positive FM test were noted more often in liver cirrhosis with disseminated intravascular coagulation (DIC) than in severe liver dysfunction without DIC. Of five cases confirmed as DIC, only three cases were diagnosed as DIC by DIC score. On the other hand, TAT and PIC were significantly elevated in DIC cases. Especially, TAT exceeded 30 ng/ml in all DIC cases. TAT was regarded to be useful for the diagnosis of DIC in severe liver dysfunction.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D004621 Embolization, Therapeutic A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage. Embolotherapy,Therapeutic Embolization,Embolizations, Therapeutic,Embolotherapies,Therapeutic Embolizations
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D000979 alpha-2-Antiplasmin A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin. alpha 2-Plasmin Inhibitor,Serpin F2,alpha(2)-Plasmin Inhibitor,alpha-2 Antiplasmin,alpha 2 Antiplasmin,alpha 2 Plasmin Inhibitor

Related Publications

K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
July 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
July 1991, Nihon Jinzo Gakkai shi,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
December 1994, Neurosurgery,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
August 1989, Biochimica et biophysica acta,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
March 1985, Asia-Oceania journal of obstetrics and gynaecology,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
January 2009, Surgery today,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
October 2006, International journal of clinical practice,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
March 2011, Medical oncology (Northwood, London, England),
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
November 1986, The Tokai journal of experimental and clinical medicine,
K Ohmoto, and S Yamamoto, and S Ideguchi, and R Yamamoto, and K Takatori, and T Ohumi, and K Hino, and Y Hirano
September 1989, Thrombosis research,
Copied contents to your clipboard!